Qu Biologics is a private clinical-stage biopharmaceutical company incorporated in the province of British Columbia, Canada, in Sept. 2007. Qu Biologics has raised $5.5M to date from angel investors and an additional $1.5M in government funding, through the National Research Council Industrial Research Assistance Program (NRC-IRAP), the Scientific Research and Experimental Development (SR&ED) Tax Incentive Program and the US National Cancer Institute (NCI).
Qu Biologics is currently seeking to raise additional funds to expand their phase 1/2 clinical trials program to include additional indications in cancer (e.g., late-stage lung cancer, late-stage colon cancer, inoperable pancreatic cancer) and autoimmune disease (e.g., rheumatoid arthritis and ulcerative colitis). In addition, Qu is looking for investment to finance the large-scale good manufacturing practices (GMP)-accredited manufacture of their lead candidate Site Specific Immunomodulator (SSI) in preparation for a phase 3 multi-national clinical trial in Crohn’s disease.
» If you are interested in learning more about investment opportunities with Qu Biologics, please enter your contact information here.